Pharmaceutical Commerce - July/August 2011 - (Page 10)

Top News Cardinal Health Opens Collaboration Center for Radiopharmaceuticals Phoenix, AZ, facility will support research and commercialization efforts for imaging agents and biomarkers C ardinal’s Center for the Advancement of Molecular Imaging (CAMI) had its official opening in July. The facility has paired (dual) cyclotrons that produce radioisotopes, especially those used in positron-emission tomography (PET), from predecessor radiochemicals; a collaboration laboratory that brings Cardinal specialists together with academic and industry researchers; “guest” laboratories where researchers can conduct experiments confidentially, then move such experimental projects into clinical trials; and a Global PET Production Control Center where clients can monitor, remotely via video, production activities in other parts of the world. John Rademacher, president of the nuclear pharmacy business of Cardinal, explains that PET imaging agents are hard to work with, let alone develop as pharmaceuticals, because they have short half-lives (that is, lose their potency and degrade into other radiochemicals) in a matter of hours or days. So, production, testing and trials need to be performed in a quick, coordinated manner. And of course, working with radioactive materials is a different level of complexity compared to most types of pharmaceuticals. CAMI “brings together the entire spectrum of capabilities that are needed to research and move new radiopharmaceuticals from bench top to FDA approval; and combines them with Cardinal’s capability to commercially manufacture, dispense and distribute the product broadly across the US,” he says. ‘PET-ready’ Cardinal Health’s Nuclear Pharmacy Services business is one of the leading suppliers of PET imaging agents and related radiopharmaceuticals in North America, running a network of 36 cyclotrons and 160 radiopharmacies, 100 of which are “PET-ready” to dispense unit doses of imaging agents (which tend to be patient- specific in dosage). The latest new cyclotron was added to the network in Augusta, GA, in June. The radiopharmaceutical business is dependent on a pair of production reactors (one in Canada, one in the Netherlands) that produce medical-grade molybdenum isotopes; this material is the starting point in cyclotrons to produce the PET imaging agents. There was a worldwide shortage, until recently, of the molybdenum, but the two reactors are now back online. Rademacher says that Cardinal manufactures, compounds or distributes over 50 radiopharmaceuticals. “There is a large number on new products that are in various stages of pre-clinical and clinical trials and today we are supporting over 20 new products that are working their way toward FDA approval or are being used as building blocks for other investigation products,” he says. CAMI is “at the center of this activity.” Express Scripts-Medco Deal Will Shake Up Pharma Distribution < continued from page 9 fifth of its business). Steve Collis, newly appointed CEO of AmerisourceBergen, told the 1,600 independent-pharmacy attendees at its National Healthcare Conference in late July that “we will help you navigate the PBM claims-processing volatility.” Pharma loses a customer Ross Muken, a Deutsche Bank analyst, told the New York Times that “there’s going to be a pretty heavy lobby from the pharma industry” against the deal, in part because it creates “an entity with a lot of power in the supply chain,” but still expected the deal to go through. Adam Fein, president of Pembroke Consulting (Philadelphia) and Pharmaceutical Commerce Editorial Board member, noted on his blog that “The old world of brand-name formulary access and rebate negotiations is rapidly fading as generics come to dominate traditional drugs. In a world of low-cost generics, the quality of care—adherence, compliance, appropriate utilization—becomes much more important than the unit price per pill. Hence, PBMs need to offer programs to payers that emphasize clinical and health care services intended to improve patient 10 July | August 2011 www.PharmaceuticalCommerce.com outcomes and lower the client’s total health care costs.” He also sees major implications for the entire PBM business after 2015, when the current wave of generic introductions slows down, potentially cutting into PBM profits. To those ends, Medco has been announcing a series of personalized medicine initiatives, including Genomics for Generics to analyze the suitability of lower-cost generics for certain patients, as well as an Advanced Oncology Solutions service that combines pharmacogenomic testing with oncology treatments; a decision-support system for oncology has been developed in conjunction with ITA Partners, Inc., a developer of clinical pathways. Meanwhile, Express Scripts has been promoting an extensive behavioral-science program, called Consumerology, to analyze patient behaviors regarding adherence and treatment options. All the same, by midafternoon on the day the merger was announced—the National Assn. of Chain Drug Stores and National Community Pharmacists Assn. issued a statement opposing the merger. “Today’s announcement that Express Scripts will buy Medco creates a middle man that is too big to play fair, and will have immense power to unfairly dominate the market. This combination will monopolize control of the supply line for brand and generic prescription drugs, threaten access to pharmacy patient care, and is a bad deal for America, for healthcare plans, for pharmacies, and—most notably—for patients,” say B. Douglas Hoey and Steven Anderson of, respectively, NCPA and NACDS. http://www.PharmaceuticalCommerce.com

Table of Contents for the Digital Edition of Pharmaceutical Commerce - July/August 2011

Pharmaceutical Commerce - July/August 2011
Contents
Op-Ed
Top News
Business/Finance
Brand Communications
Supply Chain/Logistics
Manufacturing & Packaging
Legal/Regulatory
Information Technology
PDMA Exhibitors
Meetings and Editorial Index

Pharmaceutical Commerce - July/August 2011

Pharmaceutical Commerce - July/August 2011 - Pharmaceutical Commerce - July/August 2011 (Page Cover1)
Pharmaceutical Commerce - July/August 2011 - Pharmaceutical Commerce - July/August 2011 (Page Cover2)
Pharmaceutical Commerce - July/August 2011 - Pharmaceutical Commerce - July/August 2011 (Page 3)
Pharmaceutical Commerce - July/August 2011 - Contents (Page 4)
Pharmaceutical Commerce - July/August 2011 - Contents (Page 5)
Pharmaceutical Commerce - July/August 2011 - Contents (Page 6)
Pharmaceutical Commerce - July/August 2011 - Op-Ed (Page 7)
Pharmaceutical Commerce - July/August 2011 - Top News (Page 8)
Pharmaceutical Commerce - July/August 2011 - Top News (Page 9)
Pharmaceutical Commerce - July/August 2011 - Top News (Page 10)
Pharmaceutical Commerce - July/August 2011 - Top News (Page 11)
Pharmaceutical Commerce - July/August 2011 - Business/Finance (Page 12)
Pharmaceutical Commerce - July/August 2011 - Business/Finance (Page 13)
Pharmaceutical Commerce - July/August 2011 - Business/Finance (Page 14)
Pharmaceutical Commerce - July/August 2011 - Business/Finance (Page 15)
Pharmaceutical Commerce - July/August 2011 - Brand Communications (Page 16)
Pharmaceutical Commerce - July/August 2011 - Brand Communications (Page 17)
Pharmaceutical Commerce - July/August 2011 - Brand Communications (Page 18)
Pharmaceutical Commerce - July/August 2011 - Brand Communications (Page 19)
Pharmaceutical Commerce - July/August 2011 - Supply Chain/Logistics (Page 20)
Pharmaceutical Commerce - July/August 2011 - Supply Chain/Logistics (Page 21)
Pharmaceutical Commerce - July/August 2011 - Supply Chain/Logistics (Page 22)
Pharmaceutical Commerce - July/August 2011 - Supply Chain/Logistics (Page 23)
Pharmaceutical Commerce - July/August 2011 - Supply Chain/Logistics (Page 24)
Pharmaceutical Commerce - July/August 2011 - Manufacturing & Packaging (Page 25)
Pharmaceutical Commerce - July/August 2011 - Manufacturing & Packaging (Page 26)
Pharmaceutical Commerce - July/August 2011 - Manufacturing & Packaging (Page 27)
Pharmaceutical Commerce - July/August 2011 - Legal/Regulatory (Page 28)
Pharmaceutical Commerce - July/August 2011 - Legal/Regulatory (Page 29)
Pharmaceutical Commerce - July/August 2011 - Information Technology (Page 30)
Pharmaceutical Commerce - July/August 2011 - Information Technology (Page 31)
Pharmaceutical Commerce - July/August 2011 - PDMA Exhibitors (Page 32)
Pharmaceutical Commerce - July/August 2011 - PDMA Exhibitors (Page 33)
Pharmaceutical Commerce - July/August 2011 - PDMA Exhibitors (Page 34)
Pharmaceutical Commerce - July/August 2011 - Meetings and Editorial Index (Page 35)
Pharmaceutical Commerce - July/August 2011 - Meetings and Editorial Index (Page Cover4)
http://www.nxtbook.com/nxtbooks/pharmcomm/201911
http://www.nxtbook.com/nxtbooks/pharmcomm/201909
http://www.nxtbook.com/nxtbooks/pharmcomm/201906
http://www.nxtbook.com/nxtbooks/pharmcomm/201903
http://www.nxtbook.com/nxtbooks/pharmcomm/201811
http://www.nxtbook.com/nxtbooks/pharmcomm/201809
http://www.nxtbook.com/nxtbooks/pharmcomm/201806
http://www.nxtbook.com/nxtbooks/pharmcomm/20180304
http://www.nxtbook.com/nxtbooks/pharmcomm/20171112
http://www.nxtbook.com/nxtbooks/pharmcomm/20170910
http://www.nxtbook.com/nxtbooks/pharmcomm/20170708
http://www.nxtbook.com/nxtbooks/pharmcomm/20170506
http://www.nxtbook.com/nxtbooks/pharmcomm/20170304
http://www.nxtbook.com/nxtbooks/pharmcomm/20170102
http://www.nxtbook.com/nxtbooks/pharmcomm/20161112
http://www.nxtbook.com/nxtbooks/pharmcomm/20160910
http://www.nxtbook.com/nxtbooks/pharmcomm/20160708
http://www.nxtbook.com/nxtbooks/pharmcomm/20160506
http://www.nxtbook.com/nxtbooks/pharmcomm/20160304
http://www.nxtbook.com/nxtbooks/pharmcomm/20160102
http://www.nxtbook.com/nxtbooks/pharmcomm/20151112
http://www.nxtbook.com/nxtbooks/pharmcomm/20150910
http://www.nxtbook.com/nxtbooks/pharmcomm/20150708
http://www.nxtbook.com/nxtbooks/pharmcomm/20150506
http://www.nxtbook.com/nxtbooks/pharmcomm/20150304
http://www.nxtbook.com/nxtbooks/pharmcomm/20150102
http://www.nxtbook.com/nxtbooks/pharmcomm/20141112
http://www.nxtbook.com/nxtbooks/pharmcomm/coldchaindirectory2014
http://www.nxtbook.com/nxtbooks/pharmcomm/20140910
http://www.nxtbook.com/nxtbooks/pharmcomm/20140708
http://www.nxtbook.com/nxtbooks/pharmcomm/20140506
http://www.nxtbook.com/nxtbooks/pharmcomm/20140304
http://www.nxtbook.com/nxtbooks/pharmcomm/20140102
http://www.nxtbook.com/nxtbooks/pharmcomm/dataservicedirectory
http://www.nxtbook.com/nxtbooks/pharmcomm/20131112
http://www.nxtbook.com/nxtbooks/pharmcomm/20130910_hubreport
http://www.nxtbook.com/nxtbooks/pharmcomm/20130910
http://www.nxtbook.com/nxtbooks/pharmcomm/20130708
http://www.nxtbook.com/nxtbooks/pharmcomm/20130506
http://www.nxtbook.com/nxtbooks/pharmcomm/coldchain2013
http://www.nxtbook.com/nxtbooks/pharmcomm/20130304
http://www.nxtbook.com/nxtbooks/pharmcomm/20130102
http://www.nxtbook.com/nxtbooks/pharmcomm/20121112
http://www.nxtbook.com/nxtbooks/pharmcomm/20120910
http://www.nxtbook.com/nxtbooks/pharmcomm/20120708
http://www.nxtbook.com/nxtbooks/pharmcomm/20120506
http://www.nxtbook.com/nxtbooks/pharmcomm/20120506_coldchain
http://www.nxtbook.com/nxtbooks/pharmcomm/20120304
http://www.nxtbook.com/nxtbooks/pharmcomm/20120102
http://www.nxtbook.com/nxtbooks/pharmcomm/20111112
http://www.nxtbook.com/nxtbooks/pharmcomm/20110910
http://www.nxtbook.com/nxtbooks/pharmcomm/20110708
http://www.nxtbook.com/nxtbooks/pharmcomm/20110506
http://www.nxtbook.com/nxtbooks/pharmcomm/20110304
http://www.nxtbook.com/nxtbooks/pharmcomm/20110102
http://www.nxtbook.com/nxtbooks/pharmcomm/20101112
http://www.nxtbook.com/nxtbooks/pharmcomm/20100910
http://www.nxtbook.com/nxtbooks/pharmcomm/20100708
http://www.nxtbook.com/nxtbooks/pharmcomm/20100506
http://www.nxtbook.com/nxtbooks/pharmcomm/201004
http://www.nxtbook.com/nxtbooks/pharmcomm/201003
http://www.nxtbook.com/nxtbooks/pharmcomm/20100102
http://www.nxtbook.com/nxtbooks/pharmcomm/20091112
http://www.nxtbookMEDIA.com